BIOHM Health is a leading innovator in microbiome-based products and ingredients, dedicated to improving human health by unlocking the potential of the relationship between bacteria and fungi in the microbiome. Until recently, most microbiome-based research only looked at bacteria, largely ignoring the fungal component. Founded in 2016, the company was built upon Dr Mahmoud Ghannoum's (co-founder) discovery that fungal organisms constitute an essential part of the microbiome and that when bad bacteria and fungi join forces, they create a digestive biofilm which serves to protect them. Through this discovery, combined with the identification of different microbiome types discovered by analyzing millions of microbiome testing data points, the company has been able to create targeted microbiome modulating formulas (containing a propriety blend of good bacteria, fungi, and a powerful digestive enzyme) to address certain health concerns. Biohm recently announced a partnership with Virginia Tech to further enhance its pioneering Symbiont™ platform through the use of artificial intelligence (A.I.). Symbiont, which has been peer reviewed in Gastroenterology, is a process which identifies and selects ingredients that address bacterial and fungal dysbiosis in target cohorts uncovered in BIOHM's proprietary dataset. BIOHM's dataset, one of the largest in the world, combines bacterial and fungal genetic sequencing with over 50 metadata points.Product offerings include clinically-studied Probiotics and Postbiotics and a Personalized Gut Health Test Kit.